ArticleCell2019
CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury.
Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 223 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The CAMAROS Trial: The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial
Who cites it
223 citing papers in PubMed, 2 syntheses or guidelines pooled it, 367 citations in OpenAlex.
- Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents.eLife · 2025Pooled it
- Temporal Patterning of Neurofilament Light as a Blood-Based Biomarker for Stroke: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2022Pooled it
- Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial.BMC neurology · 2024Trial
- CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.Frontiers in immunology · 2021Trial
- Review
- Cytotoxic CD4Nature aging · 2026Article
- CCR5 protects against permanent brain ischemia by suppressing neuronal ferroptosis through AMPK/ACC signaling.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Tibial bone compression promotes recovery after brain injury through osteocyte PIEZO1.Nature neuroscience · 2026Article
- CCR5Δ32 Polymorphism and Inflammatory Bowel Disease: A Case-Control and Genotype-Phenotype Study in a Polish Population.International journal of molecular sciences · 2026Article
- Brain Tissue-Derived Exosomal Proteomics Identifies Chemotaxis-Associated Protein Changes After Traumatic Brain Injury: An Exploratory Hippocampal Transcriptomic Comparison.Molecular neurobiology · 2026Article
- Ultrashort wave therapy promotes traumatic brain injury recovery by suppressing neuroinflammation.Neural regeneration research · 2026Article
- Mechanisms, Biomarkers, and Therapeutic Interventions of Neuroplasticity After Ischemic Stroke-A Scoping Review.Brain sciences · 2026Review
- Old mice fail to integrate a memory update into an existing hippocampal engram.bioRxiv : the preprint server for biology · 2026Article
- Conserved role of primary motor cortex in the control of prehension in mice and macaques.Cell reports · 2026Article
- A role for nucleolin in functional improvement in stroke.iScience · 2026Article
- Microglial Ccl4-Ccr5 signaling links systemic inflammation to synaptic loss and memory deficits in chronic kidney disease.Journal of neuroinflammation · 2026Article
- Maraviroc Attenuates Neuronal Apoptosis by Inhibiting CCR5-Mediated Microglial Activation After Subarachnoid Hemorrhage.Neurochemical research · 2026Article
- Maraviroc for Stroke Recovery (MASTER): protocol for a phase 2 double-blind placebo-controlled randomised clinical trial.BMJ open · 2026Article
- Long-range axon branching: contributions to brain network plasticity and repair.Nature reviews. Neuroscience · 2026Review
- Computational Drug Repurposing for Alzheimer's Disease via Sheaf Theoretic Population-Scale Analysis of snRNA-Seq Data.Journal of medicinal chemistry · 2026Article
163 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
Abstract
We tested a newly described molecular memory system, CCR5 signaling, for its role in recovery after stroke and traumatic brain injury (TBI). CCR5 is uniquely expressed in cortical neurons after stroke. Post-stroke neuronal knockdown of CCR5 in pre-motor cortex leads to early recovery of motor control. Recovery is associated with preservation of dendritic spines, new patterns of cortical projections to contralateral pre-motor cortex, and upregulation of CREB and DLK signaling. Administration of a clinically utilized FDA-approved CCR5 antagonist, devised for HIV treatment, produces similar effects on motor recovery post stroke and cognitive decline post TBI. Finally, in a large clinical cohort of stroke patients, carriers for a naturally occurring loss-of-function mutation in CCR5 (CCR5-Δ32) exhibited greater recovery of neurological impairments and cognitive function. In summary, CCR5 is a translational target for neural repair in stroke and TBI and the first reported gene associated with enhanced recovery in human stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.